➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Johnson and Johnson
Colorcon
McKinsey
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 6,051,379

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,051,379
Title: Cancer susceptibility mutations of BRCA2
Abstract:New mutations have been found in the BRCA2 gene. The mutations are located at nucleotide numbers 2192, 3772, 5193, 5374, 6495 or 6909 of the published nucleotide sequence of BRCA2 gene. A process for identifying a sequence variation in a BRCA2 polynucleotide sequence is disclosed. The identification process includes allele specific sequence-based assays of known sequence variations. The methods can be used for efficient, and accurate detection of a mutation in a test BRCA2 gene sample.
Inventor(s): Lescallett; Jennifer Lee (Great Falls, VA), Lawrence; Tammy (Laurel, MD), Allen; Antonette Preisinger (Severn, MD), Olson; Sheri Jon (Falls Church, VA), Thurber; Denise Bernadette (Silver Spring, MD), White; Marga Belle (Frederick, MD)
Assignee: Oncormed, Inc. (Gaithersburg, MD)
Application Number:08/984,034
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,051,379
Patent Claims:see list of patent claims

Details for Patent 6,051,379

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Oncormed, Inc. (Gaithersburg, MD) 2017-09-23 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Oncormed, Inc. (Gaithersburg, MD) 2017-09-23 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Oncormed, Inc. (Gaithersburg, MD) 2017-09-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Baxter
Express Scripts
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.